ARTICLE | Company News
Aveo Pharmaceuticals, EUSA Pharma deal
January 11, 2016 8:00 AM UTC
Aveo granted EUSA exclusive rights to develop and commercialize tivozanib in Europe, Latin America, Africa and Australasia to treat cancer, excluding conditions of the eye. Aveo has exclusive, ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151, Tokyo, Japan). This quarter, EUSA plans to submit an MAA to EMA for tivozanib as a first-line treatment for advanced renal cell carcinoma (RCC). ...